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Objectives: Accurate prediction of safe remnant liver volume to minimize complications following liver
resection remains challenging. The aim of this study was to assess whether quantification of steatosis
improved the predictive value of preoperative volumetric analysis.
Methods: Thirty patients undergoing planned right or extended right hemi-hepatectomy for colorectal
metastases were recruited prospectively. Magnetic resonance imaging was used to assess the level of
hepatic steatosis and future remnant liver volume. These data were correlated with data on postoperative
hepatic insufficiency, complications and hospital stay. Correlations of remnant percentage, remnant mass
to patient mass and remnant mass to body surface area with and without steatosis measurements were
assessed.
Results: In 10 of the 30 patients the planned liver resection was altered. Moderate–severe postoperative
hepatic dysfunction was seen in 17 patients. Complications arose in 14 patients. The median level of
steatosis was 3.8% (range: 1.2–17.6%), but was higher in patients (n = 10) who received preoperative
chemotherapy (P = 0.124), in whom the median level was 4.8% (range: 1.5–17.6%). The strongest
correlation was that of remnant liver mass to patient mass (r = 0.77, P < 0.001). However, the addition of
steatosis quantification did not improve this correlation (r = 0.76, P < 0.001).
Conclusions: This is the first study to combine volumetric with steatosis quantifications. No significant
benefit was seen in this small pilot. However, these techniques may be useful in operative planning,
particularly in patients receiving preoperative chemotherapy.
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Introduction
Liver resection, if possible, is the favoured management option for
patients with colorectal liver metastases, offering 5-year survival
rates of 35–58%1,2 and the only chance of cure. The only contrain-
dications to resection are patient fitness, presence of unresectable
extrahepatic disease and insufficient future liver remnant (FLR)
volume.3 Despite some previous studies,4–8 data on the precise
definition of insufficient FLR volume are unavailable and figures
of 20–30% have often been arbitrarily cited. Some groups have
hypothesized that the proportion of fat within the liver may be an
important factor in predicting which patients are at higher risk for
post-resection hepatic insufficiency,5,9 but the presence of fat
within the liver has not been assessed in any previous volumetric
studies. This study aimed to assess whether the quantification of
hepatic steatosis improves the ability of volumetric analysis of
FLR to predict hepatic insufficiency.
Materials and methods
Patient selection
Ethics committee approval was obtained in line with national
guidelines (ref no. 06/Q1205/168; Leeds (West) Research Ethics
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Committee). Thirty patients who had previously undergone
bowel resection and in whom right hemi-hepatectomy or
extended right hemi-hepatectomy as a first liver resection for col-
orectal metastases was planned in 2007 and 2008 were included in
the study. The decision on the procedure was made after the
evaluation of tumour distribution using magnetic resonance
imaging (MRI) of the liver, computed tomography (CT) of the
chest, abdomen and pelvis, and positron emission tomography
(PET), followed by discussion at a multidisciplinary team
meeting. This unit’s standard protocol of utilizing 2-mm slices
with and without contrast was applied; this has been described in
detail elsewhere.10 This group of patients was selected to ensure
both uniformity of disease and a high risk for hepatic insufficiency
as all of these patients would be expected to have at least 50% of
their liver resected. All were deemed to have sufficient liver func-
tion to undergo a major hepatic resection.
Demographic information was recorded. This included preop-
erative height and weight so that the body surface area (BSA)
could be calculated. Body mass index (BMI) was calculated as
weight in kilograms divided by height in metres squared (kg/m2)
and BSA was calculated as weight in kilograms to the power of
0.5 multiplied by height in centimetres to the power of 0.5 divided
by 60 (m2).
All patients underwent daily routine blood tests to assess liver
function on days 1–5 and at least every other day thereafter until
hospital discharge. Arterial blood gas analysis was carried out
routinely while patients were in high-dependency care. Encepha-
lopathy was also assessed.11 The primary outcome measures were
hepatic insufficiency and patient morbidity. Hepatic insufficiency
was quantified using the definitions described previously
(Table 1).5 Morbidity was collected and quantified according to
the Clavien grade.12 In addition, postoperative length of stay was
included as a secondary outcome measure.
MRI assessment
Examination by MRI for volumetry and steatosis assessment was
carried out with an additional scan on the day before surgery. All
MRI was performed at a field strength of 1.5 T using a Symphony
system (Siemens AG, Erlangen, Germany) and a body phased
array coil. Imaging comprised steady-state precession (TrueFISP)
sequences acquired in coronal and axial planes with a slice
thickness of 7 mm and standard spoiled gradient echo (GRE)
T1-weighted in-phase and opposed-phase sequences. In addition,
several breath-hold sequences were acquired to quantitatively
assess hepatic fat. The details of these sequences are provided in
the section on steatosis quantification.
All images were acquired during breath-holding with an acqui-
sition time of approximately 20 s per image, resulting in a total
examination time of 15–20 min.
Volumetry assessment
Slices of 7 mm in thickness were used to ensure that the entire
liver was imaged. On each slice, regions of interest were drawn to
measure the total liver volume (TLV), tumour volume (TV) and
remnant volume (RV), thus enabling the volume of each in the
whole liver to be assessed in each patient.
Steatosis quantification
In- and out-of-phase two-dimensional (2-D) spoiled GRE images
of the liver were obtained with TR = 112 ms, TE = 2.3 ms (opposed
phase) and TE = 4.6 ms (in-phase) with a flip angle of 10 °. Addi-
tional TE = 9.2 ms images were acquired to correct for T2* decay.
The hepatic fat fraction (FF) was calculated according to the
equation:
FF
S S
S
ip op
ip
=
−
⋅2
where Sip is the signal from the 10° in-phase images and Sop is the
signal intensity from the 10° opposed-phase images.
The fat fraction was calculated for three regions of interest
selected from the background normal liver parenchyma in
the predicted liver remnant and a mean was derived. These three
regions were selected randomly (by ALY and JW) to avoid regions
close to any tumour or major blood vessels. These data were used
to calculate the functional remnant liver volume (FRLV) defined
as the remnant liver volume (RLV)*(1 - FF). This methodology
has been validated at other centres13,14 and locally where the R2
value was 0.88.15
Magnetic resonance spectra were acquired from a 20 ¥ 20 ¥
10-mm voxel in the liver using a single-voxel PRESS sequence
with a TR of 5000 ms. Spectra at TEs of 30, 40, 50, 60 and 70 ms
enabled the calculation of T2 for both fat and water. The fat
fraction was calculated by measuring the areas under the T2
corrected fat and water peaks.
Predicting hepatic dysfunction
In addition to the Edinburgh model5 for predicting hepatic dys-
function (Table 1), secondary outcome measures were infective
complications, Clavien grade and postoperative stay. These
outcome measures were compared with five different assessments
using the volumetric and steatosis analyses:
1 remnant percentage: RLV/TLV ¥ 100;
2 remnant liver volume relative to body mass: RLV/body mass ¥
100;
Table 1 Definition of postoperative hepatic dysfunction based on
results from blood tests and clinical observation
Severity of hepatic dysfunctiona
0 1 2
Total serum bilirubin, mmol/l 20 21–60 >60
Prothrombin time, s above
normal
<4 4–6 >6
Serum lactate, mmol <1.5 1.6–3.5 >3.5
Encephalopathy grade No 1 and 2 3 and 4
aSeverity of hepatic dysfunction: 0, none; 1–2, mild; 3–4, moderate;
>4, severe.
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3 functional remnant liver volume relative to body mass: FRLV/
body mass ¥ 100;
4 total remnant liver volume relative to body surface area: RLV/
BSA ¥ 100, and
5 functional remnant liver volume relative to body surface area:
FRLV/BSA ¥ 100.
Validation
The resection specimen was used to calculate the displacement
volume of normal saline and was weighed using electronic scales.
Statistics
Non-parametric data are presented as medians (ranges); catego-
rical data are presented as frequencies. Correlation analyses were
carried out using Spearman’s correlation coefficient. Continuous
variables were assessed using the Mann–Whitney U-test. All
statistical tests were carried out using spss Version 14.0 (SPSS,
Inc., Chicago, IL, USA). Statistical significance was taken at 5%.
For correlation analyses, an r-value of >0.7 indicated a strong
correlation.
Results
Patient population
The 30 patients included 21 male and nine female patients with
a median age of 65 years (range: 45–82 years) (Table 2). Their
median height was 1.70 m (range: 1.54–1.94 m), median mass
was 75 kg (range: 60–113 kg) and median BMI was 26.3 kg/mm2
(range: 21.3–34.8 kg/mm2). Their median body surface area
was 1.91 m2 (range: 1.09–2.47 m2). Ten patients had received
preoperative chemotherapy, predominantly with oxaliplatin and
5-fluorouracil (5-FU).
Assessment of volume and steatosis
The median TLV was 1614 cm3 (range: 1256–2889 cm3) and
median TV was 96.5 cm3 (range: 5–865 cm3). The median level of
steatosis was 3.8% (range: 1.2–17.6%) (Fig. 1). The level of ste-
atosis was higher in patients who received preoperative chemo-
therapy (median 4.8%; range: 1.5–17.6%) relative to those who
did not (median 3.0%; range: 1.2–15.4%), although this difference
did not reach statistical significance (P = 0.124, Mann–Whitney
U-test).
Validation
The volume (saline displacement) and mass of the resected speci-
men showed an excellent correlation with one another (r = 0.967,
P < 0.001) (Fig. 2). Both the volume and mass of the resected
specimen correlated well with the predicted resection volume
(volume: r = 0.897, P < 0.001; mass: r = 0.901, P < 0.001) (Fig. 2).
Resections
Although right or extended right hemi-hepatectomy (resection of
segments V, VI, VII and VIII with or without segments I and IV)
was planned in all patients, intraoperative surgical assessment
changed the extent of resection in 10 patients (Table 2). This
decision reflected changes in the disease extent or concern that the
condition of the liver parenchyma put the patient at high risk for
postoperative hepatic insufficiency. Eight patients had solitary
tumours and the rest had multiple metastases. The median size of
the largest tumour was 40 mm (range: 11–162 mm). A total of 27
patients underwent a Pringle manoeuvre applied for a median of
30 min (range: 12–75 min). The median length of surgery was
150 min (range: 60–330 min). No patients required perioperative
blood transfusion.
Complications
There were no deaths. Overall, 14 patients suffered 19 complica-
tions: three patients experienced Clavien Grade IV complications;
six experienced Clavien Grade III complications; three experi-
enced Clavien Grade II complications, and two experienced
Clavien Grade I complications. Eight patients had infective com-
plications (five urinary tract infections, two postoperative collec-
tions and one wound infection). Other complications included
two bile leaks, one gastrointestinal bleed, one atrial fibrillation,
one pulmonary oedema, one case of transient postoperative
jaundice, one case of transient encephalopathy with four other
complications. The median postoperative stay was 10 days (range:
Table 2 Patient characteristics (n = 30)
Sex, n
Male 21
Female 9
Age, years, median (range) 65 (45–82)
Preoperative chemotherapy, n 10
Height, m, median (range) 1.70 (1.54–1.94)
Mass, kg, median (range) 75 (60–113)
Body mass index, kg/m2, median (range) 26.3 (21.3–34.8)
Body surface area, m2, median (range) 1.91 (1.65–2.47)
Total liver volume, cm3, median (range) 1614 (1256–2889)
Total tumour volume, cm3, median (range) 96.5 (5–865)
Remnant volume, cm3, median (range) 562.9 (238–1784)
Remnant liver, %, median (range) 35.36 (15–100)
Liver steatosis, %, median (range) 3.76 (1.18–17.57)
Extent of resections, n
Right trisectionectomy 2
Extended right hemi-hepatectomy 3
Right hemi-hepatectomy + caudate 1
Right hemi-hepatectomy + left-sided
metastasectomies
7
Right hemi-hepatectomy 7
Central hepatectomy 1
Right anterior sectionectomy + left-sided
metastasectomies
1
Non-anatomical resections 8
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4–79 days). Two patients had no hepatic dysfunction, 11 had mild,
14 had moderate and three had severe dysfunction (Table 3).
Correlations for predicting hepatic dysfunction
The five predictive assessments were evaluated to determine which
most accurately predicted hepatic dysfunction (Fig. 3). This
showed that remnant percentage had marginally the weakest pre-
dictive value and that total RLV to BMI, and FRLV to BMI both
showed slightly stronger correlations (Table 4). Correlations using
BSA rather than BMI were slightly less accurate in predicting
hepatic dysfunction (Table 4).
Predicting morbidity and postoperative stay
The five ways of potentially predicting the postoperative course
from the volumetric and steatosis analyses were used to assess
their value in predicting infectious complications, complications
classified by Clavien score and postoperative stay (Table 4).
All five methods of volumetric steatosis analyses were useful
in predicting infectious complications and complications accord-
ing to Clavien score, but all were more able to predict postopera-
tive stay. None of the five methods of assessment were clearly
superior at predicting infectious complications, all complications
(by Clavien grade) or postoperative stay.
Discussion
In hepatic surgery, the accurate preoperative prediction of a safe
future liver remnant in terms of volume remains challenging,
whether the liver parenchyma is normal or diseased. The increas-
ing incidence of obesity and the steatotic changes induced by
chemotherapy make this assessment more difficult. This study
aimed to take these factors into account and to examine the
impact of steatosis on volumetric assessment in terms of predict-
ing postoperative hepatic dysfunction and the occurrence of
postoperative complications. If this method of prediction proved
successful, this information could be used to help quantify perio-
perative risk in patients undergoing liver resection. It might also
be helpful in determining which patients might benefit from
further preoperative optimization by using techniques such as
portal vein embolization.16
The assessment of postoperative hepatic dysfunction remains
controversial and various systems for doing this have been sug-
gested.5,6,12,17 The 50-50 criterion appears to be the most valid at
this point,17 but none of the patients in this pilot study met this
criterion. The system used in the current study appeared to allow
a dispersion of dysfunction which has proved to be useful in other
similar studies.5 Agreement on the most useful and valid method
of assessing postoperative hepatic dysfunction would assist in the
interpretation of future studies.
This pilot study is likely to be biased because patients in whom
predicted functional liver volume was borderline (as assessed by
combining the subjective assessments of volume and steatosis
during surgery) were switched by the surgeon from resection to
an oncologically potentially more risky procedure, but one that
might decrease the risks for perioperative mortality and morbid-
ity. This stance is supported by data showing that perioperative
morbidity leads to oncologically poorer outcomes.18 It is unlikely
that this bias can be reduced in future studies.
Assessment of immediate outcome after liver resection often
relies upon perioperative morbidity, but this is problematic for
(a)
(c)
(b)
(d)
Figure 1 Magnetic resonance imaging showing (a, b) mild steatosis (3.4%) in (a) opposed-phase and (b) in-phase scans and (c, d) severe
steatosis (17.6%) in (c) opposed-phase and (d) in-phase scans
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several reasons. For example, five of 30 patients in the current
series developed culture-proven urinary tract infections. All
patients required urinary catheterization for fluid monitoring.
Whether these infections reflected impairments to the immune
system caused by hepatic dysfunction or urinary tract comorbid-
ity cannot be ascertained. The use of the recently published
Clavien system of classification represented an attempt to correct
for the severity of complications.12 Postoperative hospital stay was
thought to represent a potentially useful outcome measure.
However, this also has the potential to skew the data. One patient
underwent a right hemi-hepatectomy and achieved a dysfunction
score of only 1, but remained in hospital with cardiac complica-
tions for 79 days. This patient developed atrial fibrillation and
heart block and eventually required pacing and a prolonged
period of monitoring under the joint care of surgeons and
cardiologists.
Previous studies that have carried out volumetric analyses have
made several assumptions about uniform hepatic function.5–8
There is no evidence that these assumptions are accurate and,
in addition to variations among different segments, such as the
caudate lobe, it is likely that there are variations in peritumoral
blood flow and levels of cholestasis. Clearly, patient age, which
affects regenerative capacity,19 in addition to the fat content of the
liver,20 will affect the risk for postoperative morbidity, but age was
not factored into the current model. In addition, steatosis is
known to correlate with postoperative morbidity, but the direct
effects of marked steatosis, such as that of making the liver more
friable and therefore resection more technically demanding, must
also be considered when attempting to quantitate perioperative
risk.9,21 Correlating with a more quantitative measure of liver
function, such as indocyanide green clearance, might have helped
to address these issues to some extent.
The radiological assessment of hepatic steatosis using MRI has
been previously shown to be accurate.15,22,23 As chemotherapy
becomes increasingly common in patients prior to liver resec-
tion,24 with associated damage to the liver,25 accurate non-
invasive assessments of hepatic steatosis are likely to improve
preoperative risk stratification. This is the first study to quantify
steatosis to assist in volumetric analysis in predicting liver dys-
function following major hepatic resection. However, this study
does not show a clear predictive benefit of the addition of
steatosis quantification. This may be related to the size of the
current pilot study or to the inherent bias caused by the alter-
ations in operative technique described above, or may indicate
that the steatosis observed in this patient population was not
severe enough to impact the results. However, further investi-
gation may illuminate areas in which these techniques may
be useful, such as in the assessment of patients for live donor
liver transplantation and patients at high risk for post-resection
complications, such as those with borderline FLR volume,
obese patients, patients with metabolic syndrome and patients
who have received large amounts of potentially hepatotoxic
chemotherapy.
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Figure 2 Graphs showing strong correlations between (a) the mass
and volume of the resected specimen, (b) the mass of the resected
specimen and predicted resection volume, and (c) the volume of the
resected specimen and predicted resection volume
Table 3 Assessment of outcomes in 30 patients
Hepatic dysfunction, n
None 2
Mild 11
Moderate 14
Severe 3
Infective complications, n 8
Clavien score complications, n 14
Postoperative stay, days, median (range) 10 (4–79)
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In summary, this pilot study has shown that a measure of
hepatic steatosis is practical in volumetric analysis prior to liver
resection. However, because of the limitations described above, its
role in determining clinical decisions at this time is limited. A
significantly larger study population would be required to show
any potential benefit, at which point receiver operator character-
istic curves could be plotted to produce a more accurate cut-off
figure. There are a number of variables of importance which must
be accounted for before any volumetric score can be used to
accurately predict postoperative hepatic dysfunction.
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Figure 3 Correlations between hepatic dysfunction as assessed by the Edinburgh score5 and (a) percentage of remnant liver volume (RLV),
(b) RLV and body mass, (c) functional RLV and body mass, (d) RLV and body surface area and (e) functional RLV and body surface area
Table 4 Correlations between outcome measures and predictive indices
RLV, % TRLV : body mass FRLV : body mass TRLV : BSA FRLV : BSA
Hepatic dysfunction P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
r = -0.710 r = -0.770 r = -0.763 r = -0.715 r = -0.741
Infectious complications P = 0.071 P = 0.031 P = 0.049 P = 0.015 P = 0.028
Clavien score P = 0.025 P = 0.018 P = 0.024 P = 0.008 P = 0.011
r = -0.403 r = -0.430 r = -0.411 r = -0.476 r = -0.458
Postoperative stay P = 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
r = -0.509 r = -0.631 r = -0.621 r = -0.613 r = -0.630
RLV, remnant liver volume; TRLV, total remnant liver volume; FRLV, functional remnant liver volume; BSA, body surface area.
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